Floatz Rating
B58/100
Confidence
Indicative
Sponsor
Mayo Clinic
Modality
Small molecule
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
44Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT06905054CT.gov Pharmacologic Approaches to Preventing Primary Sclerosing Cholangitis Recurrence After Liver Transplantation | — | Recruiting | — | — | — |
NCT01142323CT.gov Pilot Study of Fenofibrate for PSC | — | Terminated | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
81High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Primary Sclerosing Cholangitis
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Fenofibrate (this asset) | Mayo Clinic | P2 | B · 58 |
| Vancomycin | Tampere University Hospital | P4 | BB |
| Ursodeoxycholic Acid | Assistance Publique - Hôpitaux de Paris | P3 | BB |
| Elafibranor | Ipsen | P3 | B |
| Aldafermin | NGM Biopharmaceuticals, Inc | P2/3 | B |
| htd1801 | HighTide Biopharma Pty Ltd | P2 | B |
| CM-101 CCL24 BLOCKING MONOCLONAL ANTIBODY | ChemomAb Ltd. | P2 | B |
| Tretinoin | Yale University | P2 | B |
| Cilofexor | Gilead Sciences | P3 | B |
+42 more in the Primary Sclerosing Cholangitis cohort
Other indications for Fenofibrate
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Inherited Lipid Metabolism Disorder | — | P4 | BBB · 74 |
| Primary Biliary Cholangitis | — | P3 | BB · 71 |
| Hypertriglyceridemia | — | P4 | BB · 69 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Fenofibrate in Primary Sclerosing Cholangitis. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/fenofibrate-primary-sclerosing-cholangitis
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →